The success of any company is through its management and leadership. MVP has a team of dedicated and experienced management specialists who seek new business opportunities and operate an efficient and profitable company. The company is overseen by its Board of Directors who offer an extensive knowledge base across business, finance and the health industry, who together, make the necessary decisions for the welfare of MVP’s shareholders and the growth of the company.
Management
Brent MacGregor
Chief Executive Officer
Mark Edwards
Chief Financial Officer and Company Secretary
Matthew Cramer
Chief of Operations and Supply Chain
Scott Courtney
Chief Scientific Officer
Neil Issa
Head of Quality
Michelle Bradney
Head of Medical Affairs
Chi Wai Ng
Head of Regulatory Affairs
Wayne Pearce
Head of Production
Sindy Martino
Head of Commercial Operations for ANZ and International
Greer Lucas
Head of People & Culture
Stefaan Schatteman
Head of Europe
Board of Directors
Gordon Naylor
Non-Executive Chairman
Gordon has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of the CSL Group, a global specialty biotechnology company that was established in Australia and grew to become Australia’s largest public company. Gordon held a range of business and functional leadership roles within CSL including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. In 2016 Seqirus was highly unprofitable with a turnover of circa $700m. By 2019 the business generated circa $150m EBIT from a turnover of $1.2b.
Gordon holds a Bachelor of Engineering (Honours), a Graduate Diploma in Computer Science and an MBA as well as being a CPA and a graduate of the Australian Institute of Company Directors.
David Williams, B.Ec (Hons), M.Ec, FAICD
Non-Executive Director
David is Managing Director of Kidder Williams Ltd, with over 35 years experience in the investment banking sector. He is also Chairman of PolyNovo Ltd and RMA Global Limited.
Max Johnston
Non-Executive Director
Mr Johnston is Chairman of Auscann Group Holdings Ltd and a former non-executive director and Chairman of Probiotec Limited. He is also a former non-executive director of Enero Group Limited and Polynovo Limited. Mr Johnston is also a Director of Prolife Foods Ltd and BARD1 Life Sciences Limited. For 11 years he was President and Chief Executive Officer of Johnson & Johnson Pacific and an Executive Director of Johnson & Johnson. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of ASMI. Mr Johnston has had extensive overseas experience during his career in leading businesses in Western and Central-Eastern Europe, Africa as well as Asia-Pacific.
Leon Hoare
Non-Executive Director
Mr Hoare is the Managing Director of Lohmann & Rauscher Australia & New Zealand (ANZ), a private EU based medical device company. Previously, he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015, one of the Smith & Nephew’s largest global subsidiaries outside the USA. He served as President of Smith & Nephew’s Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in Marketing, Divisional and General Management. His career has also included a senior role at Bristol-Myers Squibb (medical devices), and as Vice-Chair of Australia’s peak medical device industry body, Medical Technology Association of Australia.
Mr Hoare is a member of the MVP Human Resources Committee. He is also a non-executive director of PolyNovo Limited.
Philip Powell
Non-Executive Director
Non-Executive Director (since 17 December 2014)
Mr Powell, a Chartered Accountant, has an extensive finance background and commenced working in investment banking in 1996 at Hambros Corporate Finance following ten years industry experience in senior finance roles with ASX listed public company OAMPS Limited. Prior to these roles, he worked for ten years within the Assurance Division at Arthur Andersen & Co.
From January 2006 to July 2013, he was a director at Corporate Finance Advisory firm Kidder Williams. Mr Powell is also a non-executive director of RMA Global Limited and BARD1 Life Sciences Limited and a former non-executive director of PolyNovo Limited.
Philip is also Chairman of the MDI Audit and Risk Committee.
Christine Emmanuel
Non-Executive Director
Ms Emmanuel is an experienced patent and trademark attorney, and a business development professional having more than 30 years’ experience locally and internationally. Ms Emmanuel is a former Executive Manager of Business Development and Commercial at the CSIRO, where she founded and led the management of CSIRO’s IP team and managed the growth of the CSIRO equity portfolio for over 5 years. Prior to this role, Ms Emmanuel was in-house IP Counsel for Unilever in the UK and practised as a patent and trademark attorney for Wilson Gunn (UK) and Davies Collison Cave and Griffith Hack in Melbourne.
Christine is also currently non-executive director of Polynovo Ltd, IP & Commercialisation manager at RMIT University, Vice President of the Council of Patent & Trademarks Attorneys of Australia and on the Life Sciences Council of SPE Australia.
Mary Sontrop
Non-Executive Director
Mary has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration. During her 28 years with CSL Limited (ASX: CSL), Mary was an integral part of CSL’s globalisation through a series of major acquisitions. This included primary responsibility for the turnaround of unprofitable manufacturing operations. Subsequently as head of global plasma manufacturing, Mary delivered a globally integrated manufacturing network spanning four countries. As head of CSL’s Australia and New Zealand pharmaceutical business, Mary and her team delivered Australia’s most successful adolescent/adult immunisation program and achieved USFDA (US Food & Drug Administration) approval to manufacture and export CSL’s seasonal and pandemic influenza vaccines.
Mary holds a Bachelor of Applied Science, Graduate Diplomas in Quality Management and Administration (Health) and a Master of Business Administration. Mary is an experienced non-executive director (currently on the Board of IDT Australia Ltd (ASX: IDT)) and a Graduate of the Australian Institute of Company Directors. She also has significant international governance experience.
Richard Betts
Non-Executive Director
Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 20 years. Mr Betts is currently CFO at Ridley Corporation Limited and was previously CFO at Pact Group Holdings Ltd for 6 years. Prior to that he held divisional finance and other executive roles at Orica Limited, these roles provided a deep understanding of working in various jurisdictions, including North America, Europe and Asia. Mr Betts has extensive financial and governance experience within international manufacturing environments.